# Comprehensive Whole‐Course Management Strategy for Recurrent Renal Cell Carcinoma: Case Report and Literature Review

## TL;DR

This paper presents a treatment strategy for recurrent kidney cancer using a combination of PD-1 inhibitors and Axitinib.

## Contribution

The paper introduces a novel treatment approach combining PD-1 inhibitors with Axitinib for recurrent renal cell carcinoma.

## Key findings

- PD-1 inhibitors combined with Axitinib may be more effective than Axitinib alone in managing tumor metastasis.
- The proposed strategy offers an efficacious treatment option for recurrent renal cell carcinoma.

## Abstract

Renal cell carcinoma, a highly recurrent and metastatic malignancy. Drawing upon a decade‐long expertise in managing recurrent cases, we advocate the adoption of Programmed Death‐1 (PD‐1) inhibitors in conjunction with Axitinib when monotherapy with Axitinib fails to restrain tumor metastasis, thereby empowering doctors with an efficacious treatment option.